ANDOVER, Mass., Sept. 26 /PRNewswire-FirstCall/ -- TransMedics, Inc., a
privately held medical device company founded in 1998 to address the unmet
need for better, more effective organ transplant technologies, announced
today that Richard van Oostrom, formerly of Guidant Corporation, has joined
the company's board of directors. This appointment marks the latest step in
the evolution of the TransMedics board with the addition of
industry-experienced, non-investor board members.
"We are delighted that Mr. van Oostrom has joined our board at this
pivotal time in TransMedics' history," said Dr. Waleed Hassanein, president
and CEO of TransMedics. "As the European phase of the PROTECT heart trial
of our Organ Care System continues to progress, we welcome his expert input
as we move forward in our efforts to expand the reach of the trial and
towards our near term goal of product commercialization in Europe."
Mr. Van Oostrom brings more than 30 years of experience in the medical
device market to TransMedics. He is a former member of the executive board
of Guidant Corporation, past president of its European operations, and was
involved in the formation of Guidant and its subsequent IPO on the New York
Stock Exchange in 1994. He served as Chairman of the European Board till
mid-2006, when Guidant was acquired by Boston Scientific.
Previously, van Oostrom was in charge of the Medical Devices and
Diagnostic Division of Eli Lilly and Company in Europe, and was based in
London, England. Prior to that, he held executive positions at Eli Lilly in
the US, Canada, Italy, Germany and the UK. "The TransMedics Organ Care
System is a truly unique lifesaving technology that represents a real
breakthrough in transplantation," said Mr. van Oostrom. "I strongly believe
in the capability and leadership of TransMedics, and I am honored to become
a part of the visionary work being done by Dr. Hassanein and his team. I
look forward to assisting as they expand their trials and as they work
towards commercialization of this remarkable device."
A native of the Netherlands, Mr. van Oostrom studied economics in the
Netherlands and received a Master of Business Administration from the
University of Texas in 1970. In the last eight years he has been involved
as board member in several medical ventures in Europe and Israel.
About TransMedics, Inc.
Headquartered in Andover, Massachusetts, TransMedics is a privately
held medical device company founded in 1998 to address the unmet need for
better, more effective organ transplant technologies. The Company has
developed the first and only system that allows a new type of organ
transplant, called a living organ transplant. This breakthrough,
investigational technology, called an Organ Care System, is designed to
maintain organs in a warm functioning state outside of the body during
transport from organ donor to recipient. The goal of TransMedics'
technology is to improve outcomes and increase organ availability for the
growing population of patients with end-stage organ failure in need of a
transplant, bridging the ever-widening gap between the number of organs and
the number of recipients awaiting transplants. TransMedics' mission is to
enable more patients with end-stage organ failure to benefit from the
accepted medical standard of care -- successful transplantation. The
TransMedics Organ Care System is designed to help to improve the health of
organs being transplanted as well as increase the number of organs
available, improving outcomes, and reducing recovery time, hospital stays
and reliance on ongoing medical therapies. For more information, visit
SOURCE TransMedics, Inc.